

**Basel, August 1<sup>st</sup> 2020 - Cellestia Biotech AG announces appointment of Florian D. Vogl, MD, PhD as Chief Medical Officer to advance the Clinical Development Program.**

Cellestia Biotech AG, Basel, Switzerland, a clinical stage biopharma company developing innovative treatments for cancer, today announced the appointment of Florian D. Vogl, MD, PhD, as Chief Medical Officer, joining the executive management team.

Dr. Vogl is a board-certified MD. In addition, he holds a PhD in clinical pharmacology from the University of Munich and completed a postdoctoral fellowship at the International Agency for Research on Cancer in Lyon. Before moving to the biopharmaceutical industry, he had a career as a physician and clinical researcher in gynecology and oncology. Prior to joining Cellestia, Dr. Vogl was Head of Clinical Development Europe at a US-based biotech company. Previously he held roles of increasing responsibility at Novartis Oncology and Amgen in Europe and in the USA.

"I am delighted by the opportunity to join Cellestia's outstanding leadership team as we enter the next phase of growth," said Dr. Vogl. "I look forward to leading Cellestia's clinical development of novel anti-cancer therapeutics addressing currently unmet medical needs of patients. It is exciting to close an important gap in cancer therapy addressing a relevant oncogenic pathway for which, to date, no treatment option is available."

Michael Bauer, CEO and Co-Founder of Cellestia added: "Florian has joined us as our new CMO at a very important point of the company's development. The emerging data from our trial suggest that Cellestia is the first company to safely and effectively control oncogenic NOTCH pathway activation in any human cancer. Cellestia is now preparing the launch of a global clinical program in EU, USA and Asia, to advance our lead molecule CB-103 into Phase 2 in a number of indications". Cellestia announced the close of a CHF 20 mio Series B financing end of 2019 to advance the clinical lead compound as well as the R&D pipeline. Michael Bauer concluded: "Florian brings significant medical, scientific, and leadership experience from previous roles in clinical research, pharma and biotech to take a lead in advancing Cellestia's clinical development program."

### **About Cellestia Biotech AG**

Cellestia is a biopharmaceutical company specialised in research and development of first-in-class drugs targeting gene transcription factors enabling the treatment of multi-drug resistant cancers as well as a wide range of non-cancer indications. This innovative approach has successfully led to a pipeline of proprietary drug candidates. Cellestia's lead compound CB-103 is a highly potent and selective inhibitor of NOTCH transcription factor and is currently in clinical testing. Oncogenic activation of the NOTCH pathway is typically involved in highly aggressive, metastatic and multi-drug resistant, hard-to-treat cancers. Cellestia holds a worldwide exclusive license on the intellectual property rights for CB-103 and related series of analogues, for development and commercialization. The company pursues an integrated approach combining drug and personalized medicine development for patient selection.

### **Media Enquiries**

Dr. Michael Bauer, CEO  
+41 61 633 29 80  
michael.bauer@cellestia.com

Gaudenz von Capeller, CFO  
+41 79 798 64 43  
gaudenz.voncapeller@cellestia.com